Loading...
Market
What will be the outcome of Morphic Holding's lead program clinical trial results by June 30, 2025?
2
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Clinical trial results published by Morphic Holding, scientific journals, or reliable financial news sources
Story
Eli Lilly to Acquire Morphic Holding for $3.2 Billion at $57 per Share
Jul 8, 2024, 11:31 AM
Eli Lilly has announced its agreement to acquire Waltham-based Morphic Holding for approximately $3.2 billion, or $57 per share in cash. The acquisition aims to bolster Eli Lilly's immunology pipeline, particularly focusing on Morphic's lead program, a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD). This deal represents a significant premium, with Morphic's stock surging by 78% following the announcement. The acquisition is expected to enhance outcomes for patients with IBD and strengthen Eli Lilly's position in the biopharmaceutical market. Tim Springer, a Morphic founder, noted that Lilly's bid was unexpected.
View original story
Similar markets
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Highly Effective • 25%
Moderately Effective • 25%
Minimally Effective • 25%
Ineffective • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Primary endpoint met • 25%
Primary endpoint not met • 25%
Trial halted due to safety concerns • 25%
Other • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%